Constructing and Validating a Network of Potential Olfactory Sheathing Cell Transplants Regulating Spinal Cord Injury

Yan Zhang1, Yu-Shen Yang1, Wei-Can Chen1

  • 1Department of Anesthesiology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China.

PubMed

Insights

This study identifies key genes like Cd4 and Tp53 involved in spinal cord injury (SCI) treatment using cell transplantation. It reveals the toll-like receptor pathway as crucial for olfactory ensheathing cell therapy effectiveness in SCI.

Area of Science:

  • Neuroscience
  • Genomics
  • Immunology

Background:

  • Spinal cord injury (SCI) pathology involves complex primary and secondary injury mechanisms, including inflammation.
  • Cell transplantation shows promise for SCI treatment, but its molecular underpinnings require elucidation.

Purpose of the Study:

  • To identify hub genes and molecular mechanisms associated with SCI using bioinformatics.
  • To investigate the underlying mechanisms of cell intervention in SCI, specifically olfactory ensheathing cell transplantation.

Main Methods:

  • Downloaded and reanalyzed Gene Expression Omnibus (GEO) dataset GSE46988 using R.
  • Performed differential gene expression analysis, functional enrichment, and protein-protein interaction network analysis.
  • Validated key genes and pathways using quantitative real-time polymerase chain reaction (qRT-PCR).

Main Results:

  • Identified 718 differentially expressed genes (DEGs) primarily enriched in immune and inflammatory functions.
  • Discovered Cd4, Tp53, Rac2, and Akt3 as key genes potentially involved in olfactory ensheathing cell transplantation efficacy.
  • Confirmed significant enrichment of the toll-like receptor signaling pathway and validated its associated molecules (Tlr4, Nf-κb, Ikkβ, Cxcl2, Tnf-α).

Conclusions:

  • This study constructed a novel regulatory network for olfactory ensheathing cell transplantation in SCI.
  • Identified critical molecular players and pathways, offering new insights for SCI cell therapy development.